Tibremciclib - Betta Pharmaceuticals
Alternative Names: BPI-16350Latest Information Update: 28 Apr 2025
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Breast cancer; Solid tumours
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer in China (PO, Capsule)
- 10 Dec 2024 Efficacy and adverse events data from a phase III in Breast cancer presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)
- 13 Sep 2024 Efficacy and adverse event data from a phase III trial in Breast cancer presented at the 49th European Society for Medical Oncology Congress 2024 (ESMO-2024)